Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sequential VAD (vincristine, adriamycin [doxorubicin], dexamethasone) and VTD (velcade [bortezomib], thalidomide, dexamethasone) induction followed by HDT (high dose therapy) with ASCT (autologous stem cell transplant) and maintenance treatment with velcade for newly diagnosed MM (multiple myeloma)

Next Previous
Trial Profile

Sequential VAD (vincristine, adriamycin [doxorubicin], dexamethasone) and VTD (velcade [bortezomib], thalidomide, dexamethasone) induction followed by HDT (high dose therapy) with ASCT (autologous stem cell transplant) and maintenance treatment with velcade for newly diagnosed MM (multiple myeloma)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Autologous stem cell therapy; Dexamethasone; Doxorubicin; Thalidomide; Vincristine
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Dec 2009 Planned end date changed from 1 Jul 2008 to 1 Oct 2013 as reported by University Hospital Medical Information Network - Japan.
    • 01 Nov 2009 Additional lead trial centre and trial investigator identified as reported by University Hospital Medical Information Network - Japan record.
    • 01 Nov 2009 New source identified and integrated (University Hospital Medical Information Network - Japan).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top